Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials
JAMA Dec 08, 2019
Wessels AM, Tariot PN, Zimmer JA, et al. - Researchers examined how lanabecestat affects the progression of early Alzheimer disease (AD) and mild AD dementia. Two global randomized clinical trials (AMARANTH, n = 2,218; DAYBREAK-ALZ, n = 1,722) were undertaken at 257 and 251 centers and located in 15 and 18 countries or territories, respectively. Patients were randomized to receive (1:1:1) once-daily oral doses of lanabecestat 20 mg, lanabecestat 50 mg, or placebo. Outcomes revealed that in patients with early AD or mild AD dementia, lanabecestat was generally well tolerated but had no higher efficacy at both doses tested (20 mg and 50 mg) in slowing cognitive or functional decline compared with placebo.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins